GENE ONLINE|News &
Opinion
Blog

2018-10-04| PartnerAsia-Pacific

【Event Information】Med x Tech Summit Asia (MEDTEX) will debut on Nov 29th – 30th in Taipei, Taiwan!

by GeneOnline
Share To

From AIoT, Blockchain, Gene Editing, Cell Therapy, to Immune-Oncology, MEDTEX brings over 30 cross-industry global key opinion leaders to Taipei.

MEDTEX welcomes world-renowned experts Including Microsoft, Google AI, Takeda, Mayo Clinic, Merck, Teva, Harvard Medical School, NVIDIA, etc. to discuss Immune-Oncology, Delivering Personalized Healthcare through Precision Medicine, Intelligent Healthcare, Blockchain, Big Data, and other popular topics in this intensive 2-day event.

Taiwan Healthcare+ Expo is the signature expo in Asia Pacific that provides solutions for medicine, health, and care. Starting from all aspects of healthcare needs, the expo strategically connects electronics, IT, biotech, pharmaceuticals, medical devices, precision machinery, precision medicine, health management industries along with the biomedical innovators from Israel, US, Germany, Singapore, Australia together.

With 400+ major medical centers, technology, pharmaceutical, medical devices organizations participating, MEDTEX and Healthcare+ Expo are for medical professionals, IT, device, pharmaceutical, and biotech companies who wants to find new opportunities and partnering with global healthcare industry players in Asia. All expo attendees also have the opportunity to participate in the optional B2B Partnering Program.

Don’t wait till its’ too late! Come and join us, register now!

Time: Nov 29 (Thur) – 30 (Fri)
Location: Grande Luxe Banquet (Flagship)
MEDTEX Info: https://bit.ly/2NUNbIg

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Merck Strikes $50 Million Deal with ModeX For Rights to EBV Vaccine
2023-03-08
Exciting Cell & Gene Therapy Research Updates in Glaucoma and Nerve Regeneration
2023-03-08
Developments in Regenerative Medicine: Gene Delivery Tools and Cell Therapy for Parkinson’s Disease
2023-03-08
LATEST
35% Of Better Therapeutics’ Staff to be Cut to Extend the Company’s Runway
2023-03-27
Pharming’s Joenja Racks Up FDA Approval For Rare Primary Immunodeficiency
2023-03-27
Ways to Reduce Carbon Emission in Cement Manufacturing
2023-03-26
Moderna Injects $76 Million To Kickstart Lipid Nanoparticle Delivery Partnership With Generation Bio
2023-03-24
Shining a Light on Oncology with Rakuten Medical Co-CEO Takashi Toraishi
2023-03-23
Incyte’s Zynyz Secures FDA Approval for Treating a Rare and Aggressive Skin Cancer
2023-03-23
Biohaven Licenses TYK2/JAK1 Dual Inhibitor From China’s Highlight In $970 Million Pact
2023-03-23
Scroll to Top